Metoprolol Tablet

Metoprolol Tablets (Tartrate / Succinate)

Selective Beta-1 Adrenergic Receptor Antagonists

Healthy Life Pharma Private Limited, alongside our specialized global export and marketing division Healthy Inc, is a premier Indian manufacturer, CDMO partner, and wholesale exporter of advanced cardiovascular, anti-hypertensive, and critical-care therapeutics. Operating state-of-the-art, WHO-GMP certified solid dosage manufacturing facilities, we produce a complete compendial spectrum of Metoprolol Tartrate (Immediate-Release) and Metoprolol Succinate (Extended-Release) Tablets.

Our production blocks are calibrated to satisfy the strict regulatory requirements of national health ministries, state hospital tenders, and digital B2B pharmaceutical marketplace distributors across Europe, the CIS region, Africa, LATAM, and Southeast Asia by providing comprehensive technical dossiers (COA, COPP, Real-Time Stability Records, and CTD Format Dossiers).

Therapeutic Architecture & Core Portfolio

Metoprolol operates as a cardioselective beta-blocker, modifying the body’s sympathetic response to stress to protect the myocardium from excessive workload:

                  [ CARDIAC SYMIPATHETIC SIGNALING ]
                                  │
                                  ▼
               [ METOPROLOL CARDIOSELECTIVE BLOCKADE ]
                                  │
         ┌────────────────────────┴────────────────────────┐
         ▼                                                 ▼
 [ METOPROLOL TARTRATE ]                        [ METOPROLOL SUCCINATE ]
 Immediate-Release Salt                         Extended-Release Matrix
 Peak Absorption: 1-2 Hours                     Uniform Release: 24 Hours
 Target: Acute Post-MI / Arrhythmia             Target: Chronic Hypertension / CHF

1. Metoprolol Tartrate Tablets — Immediate-Release (IR) Formulations

Metoprolol Tartrate is a highly water-soluble chemical salt optimized for rapid systemic absorption and immediate therapeutic intervention.

• Mechanism of Action: It physically binds competitively to cardioselective Beta-1 ($β_{1}$) adrenergic receptors located primarily on cardiac muscle cells. This chemically blocks the binding of endogenous catecholamines (epinephrine/norepinephrine), reducing intracellular cyclic AMP ($cAMP$). The physical result is a decrease in heart rate (negative chronotropy), a reduction in cardiac output (negative inotropy), and a drop in baseline blood pressure.

• Core Product Catalog:

2. Metoprolol Succinate Extended-Release Tablets — Controlled-Release (CR/XL)

Metoprolol Succinate is formulated using advanced multi-particulate systems to establish a smooth, flat plasma concentration curve over a full 24-hour cycle.

• Mechanism of Action: Utilizing an advanced membrane-controlled delivery system, the tablet core releases thousands of individual controlled-release micro-pellets. Each pellet physically acts as an independent reservoir, chemically diffusing the active drug at a continuous, steady rate independent of gastrointestinal pH or transit motility, preventing blood pressure drops and avoiding the “peak-related” reflex tachycardia common with IR forms.

• Core Product Catalog:

Technical & Logistics Specifications

• HS Code: 3004.90.99 (Medicaments acting on the cardiovascular system / Beta-blockers)

• CAS Numbers: 56392-17-7 (Metoprolol Tartrate) / 98418-47-4 (Metoprolol Succinate)

• Packaging Configurations: 10 or 14 Tablets per Blister packed exclusively in premium, high-barrier Alu-Alu (Cold-Form Foil) or thick moisture-shield PVC/PVDC strips. Our tropicalized configurations physically seal out environmental humidity and oxygen, guaranteeing a full 36-month shelf life in demanding Zone IVb export environments.

Advanced Manufacturing Integrity & Multi-Particulate Engineering

• Pelletized Fluid-Bed Coating Technology: For our Metoprolol Succinate extended-release lines, our processing suites utilize advanced fluid-bed coater systems to spray precise ethyl-cellulose polymer membranes over active chemical drug cores. This ensures perfectly reproducible 24-hour kinetic dissolution profiles.

• Micro-Dose Blending Integrity: Because anti-hypertensive dosing demands strict precision to avoid bradycardia or sudden hypotensive episodes, we deploy automated high-speed compression matrices equipped with online weight variation checkers, physically ensuring chemical uniformity down to the microgram.

• Cross-Contamination Safeguards: To satisfy international B2B regulatory audits, our cardiovascular lines operate in HVAC-isolated, pressure-segregated manufacturing zones, physically eliminating any potential active chemical transfer between processing blocks.

Primary Indications & Therapeutic Management

• Cardiology: Treatment of Angina Pectoris, cardiac tachyarrhythmias (including atrial fibrillation rate control), and reduction of cardiovascular mortality in patients following the acute phase of a Myocardial Infarction (Heart Attack).

• Internal Medicine: Management of mild, moderate, and severe Essential Hypertension.

• Advanced Care: Stable symptomatic Chronic Heart Failure (NYHA Class II-IV) due to ischemic, hypertensive, or cardiomyopathic etiologies (specifically utilizing the Succinate salt).

• Neurology Prophylaxis: Off-label long-term prevention of chronic Migraine headaches.

Clinical Usage & Safety Protocol

• Administration Matrix: Metoprolol Tartrate (IR) must be taken physically with or immediately after food, as food physically increases its systemic bioavailability. Metoprolol Succinate (ER) should be taken once daily, preferably in the morning, swallowed physically whole with water. ER tablets can be split along the scored line if required, but they must never be crushed or chewed, as destroying the pellet coating chemically dumps the entire 24-hour dose at once.

• The Abrupt Cessation Hazard: Clinical networks must explicitly warn patients never to halt beta-blocker therapy abruptly. Sudden withdrawal can physically trigger a severe sympathetic rebound phenomenon, chemically inducing acute myocardial infarction, dangerous ventricular arrhythmias, or sudden hypertensive crises.

• Bronchospasm Awareness: While Metoprolol is cardioselective, high doses can chemically lose selectivity and partially block airway $β_{2}$ receptors. Use with physical caution in patients presenting a history of asthma or chronic obstructive pulmonary disease (COPD).

Safety Warning: POTENT CRITICAL CARDIOVASCULAR MODIFIER. For Professional Medical Supervision Only. The Rebound Hazard: Never discontinue therapy abruptly; taper doses gradually over 1 to 2 weeks to prevent severe rebound ischemia or tachyarrhythmias. Bradycardia Warning: Monitor heart rate physically; if resting pulse drops below 55-60 beats per minute, evaluate parameters chemically for sinus bradycardia. Absolute Contraindication: Do not use in cases of cardiogenic shock, severe sinus bradycardia, second or third-degree AV block (without a functioning pacemaker), sick sinus syndrome, or severe peripheral arterial circulatory disorders.

Global CDMO Services & Bulk Supply Chain

Healthy Life Pharma Private Limited and Healthy Inc provide complete, internationally validated contract manufacturing and bulk private-label export pipelines for the entire Metoprolol dosage spectrum. Whether you are bidding on an international National Health Ministry Tender, supplying a regional hospital purchasing cooperative in the CIS, or stocking an active listing on an international digital B2B Pharmaceutical Marketplace across Africa, LATAM, or Southeast Asia, we handle all mandatory entry registration documentation seamlessly.

Commercial & Bulk Procurement Inquiries:

• Corporate Head Office: Mumbai, Maharashtra, India

• Primary Manufacturing Base: Boisar, Maharashtra, India

• WhatsApp / Direct Call: +91 7710003340

• Corporate Email: info@healthyinc.co.in